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Objective: Patients with schizophrenia enrolled in a trial of long-acting injectable risperidone at multiple sites
of the Veterans Health Administration (VHA). We considered if the trial participants were representative of
the targeted group of high-utilization patients with poor adherence to anti-psychotics.
Methods: Participants' characteristics, health services utilization, and cost in the year prior to randomization
were compared to a randomly selected time-matched cohort of 10,000 other patients with schizophrenia who
were not in the trial.
Results: There were few differences in the characteristics, utilization, or cost between trial participants and
non-participants who met the key trial inclusion criterion of a history of psychiatric hospitalization in the
prior 24 months. Trial participants were more likely to be African-American (45.5% vs. 35.1%, pb .001) and
were less likely to have had a medical–surgical hospitalization in the study year (8.2% vs. 19.2% pb .001).
Compared to non-participants who did not meet the inclusion criterion, trial participants were more likely to
have a psychiatric condition in addition to schizophrenia (81.0% vs. 51.3%, pb .001), more likely to have a
substance abuse disorder (46.3% vs. 13.9% pb .001), and less likely to be adherent with their anti-psychotic
medication (21.3% vs. 37.9%, pb .001). They also incurred more than three times the annual cost ($42,563 vs.
$12,270, pb .001).
Conclusions: Trial participants appeared to be representative of the 23.3% of VHA patients with schizophrenia
whomet the key trial inclusion criterion, suggesting that trial findings will be relevant to the broader group of
high risk patients.
Published by Elsevier B.V.
1. Introduction
Lack of adherence with anti-psychotic medications is the most
common cause of poor control of schizophrenia and higher health
care costs, largely attributable to greater rates of psychiatric
hospitalization (Weiden and Olfson, 1995; Thieda et al., 2003). The
promise of better compliance and reduced hospitalization has
resulted in the replacement of conventional anti-psychotic medica-
tions by second generation drugs. Long-acting injectable (LAI)
formulations of second generation drugs have been developed with
the goals of sustained medication levels in the blood, improved
compliance and outcomes, and reduced hospitalization.
LAI risperidone (Risperdal® Consta®) is the first LAI formulation of
a second generation anti-psychotic to become available. Some
economic models have estimated that the substantial cost of this
drug may be offset by reductions in the cost of hospitalization (Chue
et al., 2005b; Edwards et al., 2005; Yang et al., 2005).
This medication has been compared to placebo in a randomized
trial (Kane et al., 2003). Observational studies have found that
switching from other anti-psychotic medications to LAI risperidone is
associated with improved outcomes and reduced hospitalization
(Fleischhacker et al., 2003; Lindenmayer et al., 2004; Moller et al.,
2005) but these studies have involved stable patients and did not
include a control group. Three randomized trials also involving stable
patients have thus far shown no advantage for LAI risperidone therapy
(Chue et al., 2005a; Bai et al., 2007; Keks et al., 2007). A review of
clinical trials of schizophrenia care found that study participants often
differ from the average patient (Gilbody et al., 2002). Trials of anti-
psychotic medications that include unrepresentative patients have
limited relevance and the trend has been towards effectiveness trials
designed to resemble normal practice (Johnsen and Jorgensen, 2008).
The U.S. Veterans Health Administration (VHA) completed
enrollment of patients in a randomized trial comparing LAI risperi-
done to the psychiatrist's choice of oral antipsychotic therapy in
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unstable schizophrenia. Because unstable patients have frequent
psychiatric hospital stays, they might benefit the most from a long-
acting medication, and they represent the group in which the
hypothesis of cost offset is most likely to prove true.
A key inclusion criterion to identify unstable patients was a history
of psychiatric hospitalization in the prior 24 months. We wished to
determine if this criterion succeeded in selecting from VHA patients
diagnosed with schizophrenia those who had the poorest medication
adherence and highest VHA health care cost. We evaluated the
potential relevance of this practical clinical trial to general VA clinical
practice by find the proportion of patients who met the trial inclusion
criterion and determining if trial participants were typical of patients
who met this criterion.
To answer these questions, we compared the utilization and cost of
trial participants in the year prior to randomization to a time-matched
cohort of 10,000 other VHA patients diagnosed with schizophrenia
who were not in the trial.
2. Materials and methods
2.1. Clinical trial cohort
A randomized clinical trial compared bi-weekly administration of
25–50 mg of LAI risperidone to the psychiatrist's choice of oral
antipsychotic medication. The trial enrolled patients receiving care in
the Veterans Health Administration (VHA) for treatment of schizo-
phrenia or schizo-affective disorder. Patients were included if they
had a psychiatric hospitalization in the previous 2 years or were
judged to be at risk of hospitalization because of increasing recent
psychiatric service use. Almost all (95%) of trial participants had
history of hospitalization within the prior 2 years. Patients provided
informed consent under a human subjects protocol at each trial site.
This paper compares service use, cost, and medication adherence
among participants in the year prior to randomization to a cohort of
10,000 users of VHA health care diagnosed with schizophrenia or
schizoaffective disorder. Trial participants were enrolled between
September 2006 and December 2008. The comparison cohort was
time-matched to trial enrollment comparison so that any secular
trends in patterns of service delivery would have the same effect on
both groups.
2.2. Comparison cohort
We created a list of all users of VHA who had at least one visit or
hospital stay with a diagnosis of schizophrenia or schizoaffective
disorder (ICD-9 codes beginning with the digits 295) during the years
of trial enrollment. After excluding trial participants, this list included
124,108 unique individuals. For each year of trial enrollment, we
sampled without replacement individuals who did not participate in
the trial who had received VHA care in that year, using a quota that
maintained the proportional distribution over time of trial enroll-
ment. A total of 10,000 individuals was selected for study. They
represented 8.1% of the VA patient population diagnosed with
schizophrenia during the period of trial enrollment. Use of these
patients' data was approved by the human subjects' review committee
of Stanford University.
Each member of the non-participant comparison group was
studied for one year. A study period was defined for each of the
three years in which non-participants were selected. To maintain
time-matching with the observations for trial participants, year-long
periods were defined to end on the mean value of the randomization
date of the trial participants who enrolled in that year.
We applied the trial inclusion criterion to non-participants by
assessing if they had an acute VA psychiatric hospitalization in the
prior 24 months. We did not have information on their use of non-VA
psychiatric hospitals. We determined which of the non-participants
who met inclusion criterion also received most of their care at a site
where trial participants were enrolled. We thus distinguished two
groups of non-participants of met inclusion criteria: those seen at trial
sites, and those seen elsewhere. If site-level effects were important,
we would expect that trial participants would be similar to the first
group but different from the second group.
We used VHA utilization files to identify the demographic
characteristics of the non-participant cohort, including age, gender,
race, and veteran service-connected disability status. We used
diagnosis codes in the hospital discharge and outpatient encounter
files to identify psychiatric and medical co-morbidities in both trial
participants and non-participants.
2.3. Cost and utilization data sources
We obtained information from the VHA Decision Support System
on the cost and utilization of hospital, residential care, outpatient
services, and pharmacy, including prescriptions for anti-psychotic
medications. We considered only care that was provided during the
one-year study time frame, excluding the portion of inpatient stays
that began before the year or ended after it. We used pharmacy data to
estimate patient adherence. Among those who received any anti-
psychotic medication, we expressed the number of days' supply that
was dispensed as a percentage of the days in the study year, and
assigned the result to one of the adherence categories described by
Gilmer (Gilmer et al., 2004). A dispensed supply that covered less than
50% of the year was defined as poor adherence, between 50% and 79%
defined as partial adherence, 80% to 110% as adherent; a supply that
was sufficient to cover more than 110% of the study year was defined
as over-filled.
We assigned inpatient care to one of three categories: acute
psychiatric, acute medical-surgical, and all other, a category that
included substance abuse treatment, nursing home, and residential
care. Costs were adjusted for inflation and expressed as 2009 U.S.
dollars using the Consumer Price Index for all goods.
2.4. Statistical methods
We compared trial participants to three other groups: (1) those
who met the key inclusion criterion at study sites but were not in the
study, (2) those who met this criterion at non-study sites, (3) other
VHA users with schizophrenia. Group differences in discrete variables
(proportions) were comparedwith logistic regression, or if therewere
multiple categories, multinomial logistic regression. Multivariate
models were used to minimize the number of tests and the effect
on study-wide Type I error. Group differences in utilization counts,
including number of outpatient visits, were evaluated with a count
data regression. Variances were found to be over dispersed and so a
negative binomial regression was used for count data (Cameron and
Trivedi, 1998). Generalized Linear Model (GLM) regressions of health
care cost avoid the inappropriate assumption of normal distribution
and homoscedastic errors (Manning and Mullahy, 2001). We
estimated the Box–Cox transformation to identify the appropriate
link function (Box and Cox, 1964) and a modified Park test to identify
the appropriate distributional family. We found the log linkage
function and gamma distribution were the most appropriate
specification.
Trial participants were compared to the three comparison groups
with respect to 57 variables on demographics, comorbidities,
utilization, and cost. These multiple comparisons substantially
increase the probability of a Type I statistical error (concluding
groups differed when they did not). For this reason, statistical
significance was reported in the text only if pb .001. At this level of
significance, the study-wide probability of a Type I statistical error is
.056 [1−(1−.001)57].
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3. Results
There were 369 trial participants. Among the non-trial cohort,
23.3% (2330/10,000) had a VA psychiatric stay in the prior 24 months,
the key inclusion criterion for trial participation. Among the non-
participants who met the inclusion criterion, 29.3% (682/2330)
received their care at one of the trial sites.
The characteristics of these groups are compared in Table 1. There
were few significant differences between trial participants and non-
participants who were met eligibility criterion. The proportion with
other psychiatric conditions and substance disorderswere similar. They
did differ by race. Trial participants were slightly younger than eligible
non-participants (51.0 vs. 53.5 years, pb .001). They were significantly
more likely to be African-American than eligible non-participants
(45.5% vs. 35.1% pb .001). This was partly due to site-level differences
in race. African-Americansmade up38.0% of eligible non-participants at
study sites, and 33.9% of eligible non-participants at other sites.
Trial participants had more co-morbidities than non-participants
without a recent psychiatric hospitalization. Trial participants were
more likely to have psychiatric conditions in addition to schizophrenia
(81.0% compared 51.3%, pb .001). They were more likely to have
depression, bipolar disorder, and Post Traumatic Stress Disorder
(PTSD). Substance abuse disorders were diagnosed in 46.3% of trial
participants, compared to 13.9% of non-participants without a history
of hospitalizations (pb .001). Trial participants were also significantly
older and more likely to be single, African-American, or have a
diagnosis of hepatitis C.
Health care utilization of the groups during the study year is
contrasted in Table 2. The study period was retrospective: it was the
year prior to randomization of trial participants, and the year prior to
application of trial enrollment criteria for the comparison cohort. Trial
participants had an average of 1.5 psychiatric stays in the study year;
the non-participants who did not meet the trial inclusion criterion
had, by definition, none. Trial participants had significantly more
outpatient visits than the non-participants who did not meet the
inclusion criterion, including significantly more individual counseling
visits (18.3 vs. 8.6, pb .001), group therapy visits (10.3 vs. 4.5,
pb .001), vocational rehabilitation visits (1.6 vs. 0.9, pb .001), and
psychiatric contacts by telephone (0.6 vs. 0.3, pb .001). There were
fewer differences in utilization between trial participants and non-
participants who met inclusion criterion, but participants had
significantly more group encounters and significantly fewer tele-
phone encounters with psychiatric providers.
Trial participants received slightly more inpatient psychiatric care
than non-participants who met the hospitalization inclusion criterion
and were treated at sites where the trial did not take place. Trial
participants had more acute psychiatric stays (1.5 vs. 1.2 stays,
pb .001) and more days of psychiatric stay (23.3 vs. 17.1 stays,
pb .001). This result may be due to site-level differences in practice, as
the number days of psychiatric stay did not differ between study
participants and eligible non-participants who received care at study
sites. Trial participants were significantly less likely to have had a
medical-surgical hospitalization in the study year than non-partici-
pants who met the inclusion criterion (8.2% vs. 19.2%, pb .001).
Table 1
Demographics and co-morbidities of CSP 555 trial and non-trial patients.
Characteristic CSP 555 trial participants
n=369
Met inclusion criterion
at site n=682
Met inclusion criterion
at non-site n=1648
Did not meet inclusion
criterion n=7670
Age, Mean (SD) 51.0 (9.3) 53.9 (10.5)* 53.4 (11.3)* 57.2 (11.4)*
Male (percent) 91.6 93.5 93.3 93.6
Race/ethnicity (percent in each category)
White 45.8 53.8† 56.1* 55.5*
Black 45.5 38.0† 33.9* 28.5*
Hispanic 5.7 5.0 7.4 8.5†
Asian/American Indian 2.7 1.6 1.2 1.7
Unknown 0.3 1.6† 1.5* 5.7*
Single/never married (percent) 85.6 82.7 80.8† 70.3*
Number of psychiatric co-morbidities (percent in each category)
None 19.0 21.4 20.1 48.7*
1 18.2 18.5 19.5 22.1
2 20.6 16.7 20.1 16.8
3+ 42.3 43.4 40.3 12.4*
Depression (percent) 38.8 35.9 35.7 19.3*
Psychoses (percent) 99.5 98.7 97.9 94.5*
Antisocial personality disorder (percent) 4.9 5.3 3.6 0.4*
Borderline personality (percent) 3.0 5.4 3.0 0.4*
Bipolar (percent) 23.6 24.2 21.5 8.2*
Post traumatic stress disorder (percent) 17.1 18.2 17.1 11.6*
Other non-psychotic disorder (percent) 52.6 54.5 54.2 32.6*
Other psychosis (percent) 25.2 23.5 20.3† 7.7*
Other personality disorder (percent) 11.7 11.6 10.1 2.1*
Substance abuse disorder (percent) 46.3 44.7 41.4 13.9*
Alcohol dependency/abuse (percent) 37.4 34.6 32.7 9.7*
Drug dependency/abuse (percent) 30.1 31.7 27.5 7.7*
Number of medical co-morbidities (percent in each category)
None 21.3 20.3 21.6 26.1†
1 25.6 23.3 21.7 23.8
2 21.5 19.7 21.6 22.1
3+ 31.6 36.6 35.1 27.9
AIDS/HIV (percent) 1.1 1.2 1.2 0.7
Congestive heart failure (percent) 2.2 4 3.3 3.0
Chronic obstructive pulmonary disease 13.3 16.6 17.6† 12.5
Diabetes (percent) 20.6 24.3 24.3 24.0
Hepatitis C (percent) 13.8 13.6 11.3 6.8*
Ischemic heart disease (percent) 6.2 9.4 9.9† 9.1
Service connected disability (percent) 50.1 56.5† 56.8† 60.1*
Significantly different from trial participants * pb .01; † pb .05.
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Anti-psychotic medication had been dispensed to most (87.0%) trial
participants. This was significantly more than the 76.8% of non-
participants who received anti-psychotic medications during the
comparable time period (pb .001). The types of anti-psychotic medica-
tions and the administrative measure of medication adherence among
thosewho received any anti-psychotics during the year are presented in
the lower portion of Table 3. These statistics exclude 28 individuals in a
long-term inpatient episode (one of N270 days). Trial participants were
significantly more likely to have received atypical anti-psychotic
medications thennon-participantswhodidnotmeet inclusion criterion.
Trial participants were significantly more likely to receive an
atypical medication than eligible non-participants at other sites.
Again, there was evidence of some site-level differences in care; there
was no significant difference between trial participants and eligible
non-participants who received care at the sites where the trial took
place.
Among those who received anti-psychotic medications, trial partic-
ipants were significantly more likely to be not adherent (a medication
possession ratio of less than 50%) and significantly more likely to be an
overfillers (with a possession ration ofmore than 110%) than thosewho
did not meet the trial inclusion criterion. There were no-significant
differences in adherence between trial participants and eligible non-
participants.
The 10,000 individuals in the comparison cohort incurred an
average of $18,754 annual health care costs, including 23.3% for acute
inpatient psychiatric care and 7.2% for anti-psychotic medications.
Mean health care costs incurred by study groups during the study year
are presented in Table 4. Trial participants incurred significantly more
cost than non-participants who had no history of hospitalization in
the prior 24 months ($42,563 vs. $12,270, pb .001). This difference
was attributable to significantly greater hospital cost ($29,882 vs.
$4200 pb .001), greater costs of outpatient care ($11,057 vs. $6824
pb .001), and greater cost for anti-psychotic medications ($1624 vs.
$1247 pb .01). There were no significant differences in the total cost of
care incurred by trial participants and eligible non-participants. Trial
participants incurred a mean of $942 cost for acute medical hospital
Table 2
Utilization and outpatient anti-psychotic medication for CSP 555 trial and non-trial patients.
Type of utilization CSP 555 trial participants
n=369
Met inclusion criterion
at site n=682
Met inclusion criterion
at non-site n=1648
Did not meet inclusion
criterion n=7670
All inpatient stays, Mean (SD) 1.9 (1.7) 2.0 (2.4) 1.7 (1.9) 0.2 (0.7)*
Acute psychiatric hospital stays per person
Number of acute psychiatric stays, Mean (SD) 1.5 (1.3) 1.4 (1.9) 1.2 (1.4)* –
Number of acute psychiatric stays, %
0 18.4 31.2* 33.1* 100.0
1 45.0 36.2* 42.0 –
2 20.6 15.5† 13.5* –
3+ 16.0 17.0 11.4† –
Total days in acute psychiatric stay, Mean (SD) 23.3 (44.0) 22.0 (43.0) 17.1 (37.5)* –
Acute medical/surgical hospital stays per person
At least one acute medical/surgical stay, % 9.2 19.2* 19.2* 9.3
Total days in acute medical/surgical stay,
Mean (SD)
0.4 (1.7) 1.5 (6.1)* 1.7 (5.4)* 0.8 (5.0)*
Other hospital stays per person
At least one other inpatient stay, % 19.0 16.0 14.0† 4.0*
Total days in other inpatient stay, Mean (SD) 12.9 (42.2) 14.3 (51.2) 11.4 (43.9) † 4.3 (33.3)*
All outpatient visits, Mean (SD) 53.2 (61.1) 55.7 (61.3) 53.7 (61.9) 34.2 (48.5)*
Individual psychiatry 18.3 (23.5) 20.6 (28.0) 18.4 (25.9) 8.6 (17.2)*
Group psychiatry 10.3 (28.6) 7.0 (20.7)* 7.1 (25.4)* 4.5 (22.1)*
Vocational rehabilitation 1.6 (10.5) 1.8 (13.1) 1.4 (10.2) † 0.9 (10.4)*
Telephone psychiatry 0.6 (2.2) 1.0 (3.3)* 1.0 (3.3)* 0.3 (1.8)*
Other psychiatry 1.0 (1.9) 2.3 (14.1)* 2.3 (8.8)* 1.4 (8.5)*
Medical/surgical 8.6 (9.4) 9.1 (9.4) 9.4 (10.4) 7.7 (9.3)
Other ambulatory care 12.8 (19.5) 14.0 (16.6) 14.1 (20.5) 10.7 (16.5)*
Significantly different from trial participants * pb .01; † pb .05
Table 3
Outpatient prescription medication for trial and non-trial patients.
Description CSP 555 trial participants
n=369
Met inclusion criterion
at site n=682
Met inclusion criterion
at non-site n=1648
Did not meet inclusion
criterion n=7670
Excluded because N270 days of stay 2 6 9 11
Non-institutionalized patients 367 676 1639 7659
Non-institutionalized patients who
received anti-psychotic medication
Number 319 567 1369 5879
Percent 87.0 84.0 83.6 76.8*
Type of anti-psychotic medication,‡%
Conventional only 4.7 7.6 8.5† 15.8*
Atypical only 80.3 75.3 69.8* 72.9*
Both conventional and atypical 15.0 17.1 21.7* 11.3†
Received depot medication,‡% 8.8 17.3* 17.2* 6.9
Adherence,‡%
Not adherent 28.8 28.2 25.4 21.4*
Partially adherent 22.3 19.0 19.7 18.3*
Adherent 21.3 23.1 24.1 37.9
Over fillers 27.6 29.6 30.8 22.4†
Significantly different from trial participants * pb .01; † pb .05.
‡Among those who received an anti-psychotic medication who were not institutionalized (less than 270 days of stay).
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says, significantly less than the $2999 incurred by eligible non-
participants at study sites (pb .01) and the $3301 incurred by eligible
non-participants at other sites (pb .001).
4. Discussion
The key trial inclusion criterion, psychiatric hospitalization in the
prior 24 months, succeeded in identifying the more seriously ill, more
costly, and less medication adherent patients with schizophrenia and
schizoaffective disorder, the individuals most likely to benefit from
injectable risperidone. Trial participants were more likely to have
psychiatric and substance abuse comorbidities recorded in adminis-
trative data than non-participants who did not meet the inclusion
criterion, including depression, bipolar disorder, and Post Traumatic
Stress Disorder. Trial participants incurred a mean of $42,563 in
annual health care cost, more than 3 times the $12,270 incurred by
non-participants who did not meet this inclusion criterion.
Trial participants had greater problems with medication adher-
ence. Among ambulatory patients with schizophrenia who received at
least one prescription for an anti-psychotic medication, just 21.3% of
trial participants had good adherence, significantly less than the 37.9%
adherence among non-participants who did not meet the inclusion
criterion. This poor adherence involved insufficient medication and
also excessive supply. Both under use and oversupply of medication
are associatedwithworse outcomes (Valenstein et al., 2002; Gilmer et
al., 2004; Eaddy et al., 2005).
Trial participants appeared to be representative of a large but
distinctive segment of patients with schizophrenia or schizoaffective
disorder. The trial inclusion criterion was met by 23.3% of a random
selection of VHA patients with these illnesses. There were few observ-
able differences between trial participants and non-participants who
met the trial inclusion criterion, suggesting that the trial findings will
be relevant to the broader group of high risk patients.
Other studies have compared participants in schizophrenia trials
to non-participants who met enrollment criteria and received care in
the same health care setting. A study of psychiatric inpatients found
trial participants were younger and had a more recent onset of illness
than non-participants (Hofer et al., 2000). A study of patients in
community mental health centers found participants were younger
and usedmore services; in trials that included patients with substance
use disorders, participants were more likely to be minorities and less
likely to have medical comorbidities (Woods et al., 2000). We found
similar results in this study. Trial participants were slightly younger,
more likely to be African-American, and more likely to have had a
recent medical–surgical hospitalization than non-participants who
met inclusion criteria. Part of the difference in racial characteristics
was attributable to site-level effects. Among VA patients with
schizophrenia who met trial inclusion criteria, the proportion that
was African-American was greater at trial sites. We did not find that
trial participants used more services than non-participants; however,
high utilization (recent hospitalization) was the inclusion criterion
that was applied to both groups.
This study has limitations imposed by its reliance on administra-
tive data. The accuracy and completeness of diagnostic coding is
uncertain, especially among patients with little health care utilization.
Although the trial inclusion criterion would be met by a non-VA
hospital stay, we had no information on the psychiatric hospitaliza-
tions outside of VHA of non-participants. As a result, we have
understated the number of non-participants who would have met the
trial inclusion criterion. We lacked information on costs outside the
VHA system. Total cost of care is thus understated. Although VHA
patients use other providers, those with mental health services
conditions are less likely to do so (Petersen et al., 2010).
We determined that individuals with schizophrenia treated in the
VHA health care system in the years 2006–2008 incurred a mean of
$18,754 in annual health care costs, 7.2% of which was for anti-
psychotic medications. Although total cost of care is consistent with
other studies, VHA has lower medication cost. VHA has negotiated
substantial discounts from pharmaceutical suppliers (United States
Congress. Congressional Budget Office, 2005).
One study found VHA medication costs to be 40% less than other
U.S. health care sponsors (Render et al., 2003). A study of California
Medicaid recipients with schizophrenia found mean annual costs of
$14,103 in 2001, 20.2% of which was anti-psychotic medication
(Duggan, 2005). A multi-site observational study of schizophrenia
patients in VHA, community mental health centers, and community
and state hospitals found mean annual costs of $16,098 in the period
1997–2003, with 23.4% of these costs attributed to anti-psychotics
(Zhu et al., 2008).
The VA trial of LAI risperidone enrolled patients with poor
medication adherence, high rates of psychiatric hospitalization, and
significant co-morbidities, a group that might best be able to benefit
from the expense of a long-acting second generation anti-psychotic
medication. Trial participants appeared to be representative of the
23.3% of patients who had a psychiatric hospitalization in the previous
24 months, a large high-risk population. We believe that this is one of
Table 4
Average costs for trial and non-trial patients (2009 U.S. dollars).
Type of cost CSP 555 trial participants
n=369
Met inclusion criterion
at site n=682
Met inclusion criterion
at non-site n=1648
Did not meet inclusion
criterion n=7670
Inpatient
Acute psychiatric hospital stays 23,087 21,101 17,736.† –
Acute medical/surgical hospital stays 942 2999.* 3301.* 1914.†
Other hospital stays 5852 6520 4900 2287.†
Total inpatient 29,882 30,620 25,936 4200.*
Outpatient
Individual psychiatry 4373 5104 4232 1891.*
Group psychiatry 1333 1105 893 563.*
Vocational rehabilitation 360 283 262 151
Telephone psychiatry 84 108 111 39.†
Other psychiatry 78 206 226 81
Medical/surgical 2929 2820 2646 2023.*
Other ambulatory care 1900 2316 2439 2076
Total outpatient 11,057 11,942 10,807 6824.*
Anti-psychotic medication
Conventional only 31 38 46 48
Atypical only 1593 1714 1566 1199.*
Total anti-psychotic medications 1624 1753 1612 1247.*
Total, average cost per patient 42,563 44,315 38,356 12,270.*
Significantly different from trial participants * pb .01; † pb .05.
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the first studies to compare trial participants to patients with a similar
diagnosis, and to describe the population of a national health care
system whose care may be guided by trial findings.
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